Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

PAREXEL International Corporation (PRXL)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow PAREXEL's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
PAREXEL historical data, for real-time data please try another search
88.08 0.00    0.00%
29/09 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 88.07 - 88.10
PAREXEL 88.08 0.00 0.00%

PAREXEL International Corporation Company Profile

 
Get an in-depth profile of PAREXEL International Corporation, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

18900

Equity Type

ORD

Parexel International Corporation operates as a biopharmaceutical outsourcing company that provides clinical research and logistics, medical communications, consulting, and technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company offers clinical development, including translational medicine, early phase, phase II-III, phase IIIb/IV, biostatistics, clinical data management, clinical supply chain management, decentralized clinical trials, medical monitoring and consulting, medical writing, patient sensors, pharmacovigilance, and risk-based quality management (RBQM); outsourcing services, including functional services provider (FSP), strategic partnerships, and meeting management and logistics; consulting, including regulatory affairs consulting, clinical development strategy and planning, GxP compliance consulting, regulatory outsourcing, clinical trial regulatory services, market access and HEOR consulting, and commercial strategy (health advances); medical affairs, including the medical affairs company (TMAC), medical communications, and expanded access services; real-world evidence and late phase, including epidemiology, observational studies, and real-world data sciences; industry solutions, including pharma solutions and medical devices; and development phase solutions. Parexel International Corporation has strategic agreements with Microsoft Corporation, Synairgen plc, and CTC North GmbH & Co. KG. The company was incorporated in 1983 and is based in Newton, Massachusetts, with branches in Waltham and Billerica, Massachusetts, and Uxbridge, United Kingdom. It has additional locations throughout the world.

Contact Information

Address 275 Grove Street 101C
Newton, 02466
United States
Phone 617 454 9300
Fax -
Web www.parexel.com
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

PRXL Comments

Write your thoughts about PAREXEL International Corporation
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Stanley Ward
Stanley Ward Feb 15, 2015 8:59PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Looks good o me!
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email